Neurocrine Biosciences Chief Medical Officer Reports PRSU Vesting & Tax Withholding
NEUROCRINE BIOSCIENCES INC
Subscribe to track NBIX
Premium users can add ticker alerts and receive realtime notification updates.
Filing Summary
š Form 4 Filed: NBIX (NEUROCRINE BIOSCIENCES INC) š¤ Insider: Keswani Sanjay Chandru (Chief Medical Officer) š Date: 2026-09-11 š Transaction: PRSU Vesting (3,914 shares) & Tax Withholding of 2,112 shares @ $156.22 ($329,936.64) š¦ Ending Balance: 3,281 shares (Direct) ā” Significance: Low (Routine Vesting / Tax Withholding)
Comprehensive Analysis
Executive Summary
On September 15, 2026, Neurocrine Biosciences, Inc. ($NBIX) filed a Form 4 disclosing transactions by Chief Medical Officer Sanjay Chandru Keswani on September 11, 2026. The filing reports the certification and vesting of 3,914 Performance Restricted Stock Units (PRSUs) and the subsequent withholding of 2,112 shares to cover associated tax liabilities at a price of $156.22 per share ($329,936.64 total value).
Transaction Breakdown
- PRSU Vesting (Code A): 3,914 shares acquired at $0.00 following the certified achievement of performance metrics.
- Tax Withholding (Code F): 2,112 shares withheld by the issuer at $156.22 per share to satisfy tax obligations.
- Net Change: Direct holdings increased by net 1,802 shares to 3,281 shares.
Market & Trading Significance
This is classified as Low Significance from an investment sentiment perspective, as it represents routine equity compensation vesting and standard tax withholding rather than open-market buying or discretionary selling.
Get Real-Time Alerts
Join our community to receive instant notifications when high-significance filings are published
Important Disclaimer
This content is drawn from public SEC filings and may contain errors. It is for informational purposes only and is not investment, legal, or tax advice.
Nothing here is a recommendation to buy, sell, or hold any security. Do your own due diligence.